Raymond James Financial upgraded shares of ADMA Biologics (NASDAQ:ADMA – Free Report) to a moderate buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports.
A number of other equities research analysts have also weighed in on ADMA. Zacks Research lowered ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 26th. Wall Street Zen lowered ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Canaccord Genuity Group lowered their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Mizuho lowered their price objective on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $19.67.
Get Our Latest Analysis on ADMA Biologics
ADMA Biologics Price Performance
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The firm had revenue of $114.49 million during the quarter, compared to analyst estimates of $139.98 million. During the same quarter last year, the firm earned $0.11 EPS. ADMA Biologics’s quarterly revenue was down .3% on a year-over-year basis. On average, equities analysts predict that ADMA Biologics will post 0.84 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, Director Jerrold B. Grossman bought 12,500 shares of ADMA Biologics stock in a transaction on Monday, May 11th. The shares were bought at an average price of $8.01 per share, with a total value of $100,125.00. Following the acquisition, the director directly owned 513,884 shares in the company, valued at approximately $4,116,210.84. This represents a 2.49% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.90% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. Western Wealth Management LLC bought a new position in ADMA Biologics during the 1st quarter worth approximately $31,000. Bank of America Corp DE lifted its holdings in shares of ADMA Biologics by 107.5% in the 1st quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock worth $36,019,000 after purchasing an additional 2,071,338 shares during the last quarter. Amundi lifted its holdings in shares of ADMA Biologics by 62.9% in the 1st quarter. Amundi now owns 51,761 shares of the biotechnology company’s stock worth $466,000 after purchasing an additional 19,985 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of ADMA Biologics by 24.0% in the 1st quarter. California State Teachers Retirement System now owns 279,124 shares of the biotechnology company’s stock worth $2,515,000 after purchasing an additional 53,988 shares during the last quarter. Finally, Royal Bank of Canada lifted its holdings in shares of ADMA Biologics by 448.8% in the 1st quarter. Royal Bank of Canada now owns 929,326 shares of the biotechnology company’s stock worth $8,373,000 after purchasing an additional 759,984 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.
About ADMA Biologics
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
Read More
- Five stocks we like better than ADMA Biologics
- As Shares Fall, Analyst Are Boosting their Broadcom Price Targets
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
